Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees A Spannhoff, YK Kim, NJM Raynal, V Gharibyan, MB Su, YY Zhou, J Li, ... EMBO reports 12 (3), 238-243, 2011 | 225 | 2011 |
Targeting CDK9 reactivates epigenetically silenced genes in cancer H Zhang, S Pandey, M Travers, H Sun, G Morton, J Madzo, W Chung, ... Cell 175 (5), 1244-1258. e26, 2018 | 207 | 2018 |
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory NJM Raynal, J Si, RF Taby, V Gharibyan, S Ahmed, J Jelinek, ... Cancer research 72 (5), 1170-1181, 2012 | 144 | 2012 |
Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer NJM Raynal, JT Lee, Y Wang, A Beaudry, P Madireddi, J Garriga, ... Cancer research 76 (6), 1494-1505, 2016 | 108 | 2016 |
Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition GG Malouf, JH Taube, Y Lu, T Roysarkar, S Panjarian, MRH Estecio, ... Genome biology 14, 1-17, 2013 | 100 | 2013 |
Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine M Lemaire, LF Momparler, NJM Raynal, ML Bernstein, RL Momparler Cancer chemotherapy and pharmacology 63, 411-416, 2009 | 76 | 2009 |
Antileukemic activity of genistein, a major isoflavone present in soy products NJM Raynal, L Momparler, M Charbonneau, RL Momparler Journal of Natural Products 71 (1), 3-7, 2008 | 76 | 2008 |
Repositioning FDA-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome NJM Raynal, EM Da Costa, JT Lee, V Gharibyan, S Ahmed, H Zhang, ... Molecular cancer therapeutics 16 (2), 397-407, 2017 | 75 | 2017 |
Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer M Lemaire, GG Chabot, NJM Raynal, LF Momparler, A Hurtubise, ... BMC cancer 8, 1-10, 2008 | 72 | 2008 |
DNA methylation signature reveals cell ontogeny of renal cell carcinomas GG Malouf, X Su, J Zhang, CJ Creighton, TH Ho, Y Lu, NJM Raynal, ... Clinical Cancer Research 22 (24), 6236-6246, 2016 | 53 | 2016 |
Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia. NJ Raynal, M Charbonneau, LF Momparler, RL Momparler Oncology research 17 (5), 223-230, 2008 | 45 | 2008 |
Epigenetic synergy between decitabine and platinum derivatives T Qin, J Si, NJM Raynal, X Wang, V Gharibyan, S Ahmed, X Hu, C Jin, ... Clinical epigenetics 7, 1-14, 2015 | 42 | 2015 |
Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation EM Da Costa, G Armaos, G McInnes, A Beaudry, G Moquin-Beaudry, ... Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019 | 34 | 2019 |
DNA Methylation–Targeted Drugs EM Da Costa, G McInnes, A Beaudry, NJM Raynal The cancer journal 23 (5), 270-276, 2017 | 34 | 2017 |
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells C Dominici, N Sgarioto, Z Yu, L Sesma-Sanz, JY Masson, S Richard, ... Clinical Epigenetics 13, 1-15, 2021 | 31 | 2021 |
3-Deazauridine enhances the antileukemic action of 5-aza-2′-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase NJM Raynal, LF Momparler, GE Rivard, RL Momparler Leukemia research 35 (1), 110-118, 2011 | 25 | 2011 |
Hypomethylation of TET2 target genes identifies a curable subset of acute myeloid leukemia J Yamazaki, R Taby, J Jelinek, NJM Raynal, M Cesaroni, SA Pierce, ... Journal of the National Cancer Institute 108 (2), djv323, 2016 | 21 | 2016 |
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features GG Malouf, T Tahara, V Paradis, M Fabre, C Guettier, J Yamazaki, H Long, ... Epigenetics 10 (9), 872-881, 2015 | 19 | 2015 |
DNA methyltransferase inhibitors NJM Raynal, JPJ Issa Drug discovery in cancer epigenetics, 169-190, 2016 | 14 | 2016 |
Cadmium uptake in isolated adrenocortical cells of rainbow trout and yellow perch NJ Raynal, A Hontela, C Jumarie Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology …, 2005 | 14 | 2005 |